| Tiziana Life Sciences' foralumab reduced neuroinflammation in Alzheimer's patient, study shows |
Tiziana Life Sciences Ltd (NASDAQ:TLSA)' investigational therapy intranasal foralumab has been shown to significantly reduce neuroinflammation in a 78-year-old patient with moderate Alzheimer's disease (AD), a newly published study has shown. The study, published in the Journal of Clinical Nuclear Medicine, was led by Dr Tarun Singhal and Dr Howard Weiner of Brigham and Women's Hospital, a founding member of the Mass General Brigham healthcare system. |
proactiveinvestors.com |
2025-05-15 13:43:54 |
Czytaj oryginał (ang.) |
| Tiziana Life Sciences Announces Purchase of Shares by Chairman |
NEW YORK, May 12, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human anti-CD3 monoclonal antibody, today announces that its Executive Chairman and Founder, Mr. |
globenewswire.com |
2025-05-12 11:00:00 |
Czytaj oryginał (ang.) |
| Tiziana Life Sciences reports reduced brain inflammation in Alzheimer's patient treated with nasal foralumab |
Tiziana Life Sciences Ltd (NASDAQ:TLSA) said on Friday that a patient with moderate Alzheimer's disease showed a marked reduction in brain inflammation after three months of treatment with its lead drug candidate, intranasal foralumab, under an expanded access program. A PET scan revealed a significant decrease in microglial activation—an indicator of neuroinflammation linked to Alzheimer's progression—according to data presented by Dr Howard Weiner at the 2025 AD/PD Conference in Vienna. |
proactiveinvestors.com |
2025-05-09 13:31:37 |
Czytaj oryginał (ang.) |
| Tiziana Life Sciences Announces Significant Reduction in Microglia Activation in PET Scan of Moderate Alzheimer's Patient Treated with Intranasal Foralumab |
NEW YORK, May 09, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human anti-CD3 monoclonal antibody, today announced results of a PET scan showing a marked reduction in microglia activation associated with neuroinflammation in a patient suffering from moderate Alzheimer's disease (AD) who was treated for three months with intranasal foralumab under an expanded access program. The microglial TSPO PET scan revealed a significant decrease in microglia activation, a key indicator of neuroinflammation associated with Alzheimer's disease progression. |
globenewswire.com |
2025-05-09 11:00:00 |
Czytaj oryginał (ang.) |
| Tiziana shares surge 21% on promising multiple sclerosis data |
Tiziana Life Sciences Ltd (NASDAQ:TLSA) shares jumped 21% in early trading Tuesday after the company reported positive early-stage data for its experimental multiple sclerosis treatment, nasal foralumab. The open-label study involved 10 patients with non-active secondary progressive MS, a form of the disease where disability progresses despite the absence of relapses and few treatment options exist. |
proactiveinvestors.com |
2025-05-06 14:57:59 |
Czytaj oryginał (ang.) |
| Tiziana reports encouraging results for nasal MS drug in early study |
Tiziana Life Sciences Ltd (NASDAQ:TLSA) said Tuesday that its experimental multiple sclerosis therapy, nasal foralumab, showed positive results in an early-stage study, with patients experiencing stabilised disease progression and reduced signs of brain inflammation. The open-label study followed 10 patients with non-active secondary progressive multiple sclerosis, or na-SPMS, a difficult-to-treat form of the disease in which disability worsens even in the absence of relapses. |
proactiveinvestors.com |
2025-05-06 12:27:50 |
Czytaj oryginał (ang.) |
| Tiziana Life Sciences Announces Comprehensive Positive Results from Study of Nasal Foralumab in Patients with Multiple Sclerosis |
Meaningful Fatigue score reduction seen in study is a critically important quality of life (QoL) measure for Multiple Sclerosis patients. All patients experienced stabilization of Expanded Disability Status Scale (EDSS) scores. |
globenewswire.com |
2025-05-06 11:00:00 |
Czytaj oryginał (ang.) |
| Tiziana Life Sciences announces patient dosing in Phase 2 MS trial at University of Massachusetts |
Tiziana Life Sciences Ltd (NASDAQ:TLSA) announced that the University of Massachusetts has commenced dosing patients in its ongoing Phase 2 trial of its lead candidate intranasal foralumab, a fully human anti CD3 monoclonal antibody, for non-active secondary progressive multiple sclerosis (na-SPMS). UMass joins Brigham and Women's Hospital, Yale Multiple Sclerosis Center, and Johns Hopkins University in actively enrolling and treating trial participants. |
proactiveinvestors.com |
2025-04-23 12:38:02 |
Czytaj oryginał (ang.) |
| Tiziana Life Sciences Announces University of Massachusetts Commences Dosing Intranasal Foralumab in Phase 2 Multiple Sclerosis Trial |
NEW YORK, April 23, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced that dosing has commenced at the fourth clinical site in its ongoing Phase 2 trial evaluating intranasal foralumab in patients with non-active secondary progressive multiple sclerosis (na-SPMS). |
globenewswire.com |
2025-04-23 11:00:00 |
Czytaj oryginał (ang.) |
| Tiziana Life Sciences begins patient dosing in Phase 2 MS trial at Johns Hopkins |
Tiziana Life Sciences Ltd (NASDAQ:TLSA) has announced that Johns Hopkins University has begun dosing patients in its Phase 2 clinical trial evaluating intranasal foralumab for non-active Secondary Progressive Multiple Sclerosis (na-SPMS). This marks the third clinical site for the trial, alongside Brigham and Women's Hospital and Yale Medical Center. |
proactiveinvestors.com |
2025-04-02 13:04:20 |
Czytaj oryginał (ang.) |
| Tiziana Life Sciences Announces Johns Hopkins University Commences Dosing Nasal Foralumab in Phase 2 Multiple Sclerosis Clinical Trial |
NEW YORK, April 02, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced dosing has commenced at Johns Hopkins University (JHU) Autoimmunity Center of Excellence, the third clinical site in its Phase 2 trial evaluating intranasal foralumab for the treatment of non-active Secondary Progressive Multiple Sclerosis (na-SPMS). |
globenewswire.com |
2025-04-02 12:00:00 |
Czytaj oryginał (ang.) |
| Tiziana Life Sciences begins dosing in Phase 2 trial for intranasal foralumab in SPMS |
Tiziana Life Sciences Ltd (NASDAQ:TLSA) said on Tuesday it has begun dosing patients at Yale MS Center in its multicenter Phase 2 trial evaluating intranasal foralumab, a fully human anti-CD3 monoclonal antibody, for non-active secondary progressive multiple sclerosis (na-SPMS). The study, which aims to assess the safety and effectiveness of foralumab in mitigating disease progression, is also enrolling patients at Johns Hopkins, UMass Medical Center, and Brigham and Women's Hospital, the company said in a statement. |
proactiveinvestors.com |
2025-03-25 11:28:55 |
Czytaj oryginał (ang.) |
| Tiziana Life Sciences Announces Yale University Commences Intranasal Foralumab Dosing in Phase 2 Multiple Sclerosis Trial |
NEW YORK, March 25, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced dosing of new patients at Yale MS Center which is participating in our multicenter Phase 2 clinical trial evaluating intranasal foralumab for non-active Secondary Progressive Multiple Sclerosis (na-SPMS). |
globenewswire.com |
2025-03-25 10:00:00 |
Czytaj oryginał (ang.) |
| Tiziana Life Sciences to Present at the 37th Annual Roth Conference |
NEW YORK, March 17, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced that the CEO of Tiziana Life Sciences, Ivor Elrifi, will be presenting during a fireside chat at the 37th Annual ROTH Conference and host 1x1 investor meetings. The Conference is being held March 16-18, 2025, in Dana Point, California. This year's event will consist of 1-on-1 / small group meetings, analyst-selected fireside chats, industry keynotes and panels with executive management attending from approximately 450 private and public companies in a variety of growth sectors. |
globenewswire.com |
2025-03-17 10:00:00 |
Czytaj oryginał (ang.) |
| Tiziana Life Sciences Regains Compliance with Nasdaq Listing Minimum Bid Price Rule |
NEW YORK, March 14, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced that it has received a notification from the Nasdaq Stock Market LLC (“Nasdaq”) Listing Qualifications Department informing the Company that it has regained compliance with the Nasdaq listing minimum bid price requirement for continued listing on the Nasdaq Capital Market exchange. |
globenewswire.com |
2025-03-14 10:30:00 |
Czytaj oryginał (ang.) |
| Tiziana submits FDA investigational new drug application |
Tiziana Life Sciences Ltd has filed an investigational new drug application with the Food and Drug Administration for a clinical trial in Amyotrophic Lateral Sclerosis (ALS). Tiziana, which is advancing lead candidate intranasal foralumab, said on Tuesday it planned a phase two trial including 20 patients upon clearance. |
proactiveinvestors.com |
2025-03-04 11:38:15 |
Czytaj oryginał (ang.) |
| Tiziana Life Sciences Files Investigational New Drug Application with FDA for ALS Phase 2 Clinical Trial |
NEW YORK, March 04, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced the submission of its Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for a phase 2 clinical trial in ALS. |
globenewswire.com |
2025-03-04 10:00:00 |
Czytaj oryginał (ang.) |
| Tiziana Life Sciences nasal anti-CD3 therapy shows promise in treating traumatic brain injury, study reveals |
Tiziana Life Sciences Ltd (NASDAQ:TLSA) has announced the publication of a groundbreaking study in Nature Neuroscience that demonstrates promising results for its nasal anti-CD3 therapy in treating traumatic brain injury (TBI). TBI is a leading cause of death and disability worldwide, and current treatments fail to address its long-term effects. |
proactiveinvestors.com |
2025-02-27 12:26:39 |
Czytaj oryginał (ang.) |
| Tiziana Life Sciences Announces Groundbreaking Study Published in Nature Neuroscience Demonstrating Positive Results for Nasal Anti-CD3 Therapy in Traumatic Brain Injury |
Traumatic brain injury is a leading cause of death and disability Currently, there is no treatment to prevent the long-term effects of traumatic brain injury Findings could translate into treating intracerebral hemorrhage or stroke NEW YORK, Feb. 27, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced the publication of a landmark study in Nature Neuroscience demonstrating that nasal administration of Tiziana's anti-CD3 monoclonal antibody significantly reduced neuroinflammation and improved recovery. |
globenewswire.com |
2025-02-27 10:00:00 |
Czytaj oryginał (ang.) |
| Tiziana Life Sciences nearing completion of long COVID study on foralumab |
Tiziana Life Sciences Ltd (NASDAQ:TLSA) announced that it expects to complete its preclinical study evaluating its nasal anti-CD3 foralumab as a potential treatment for long COVID in the second quarter of 2025. The company said the study aims to validate foralumab's ability to mitigate persistent brain inflammation, a key driver of the neurological and psychiatric symptoms associated with long COVID. |
proactiveinvestors.com |
2025-02-25 12:02:34 |
Czytaj oryginał (ang.) |
| Tiziana Life Sciences Announces Long Covid Study to Complete in Second Quarter |
NEW YORK, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced that a nasal anti-CD3 (foralumab) preclinical study is nearing completion, and that foralumab could offer a novel and effective treatment for long COVID. |
globenewswire.com |
2025-02-25 10:00:00 |
Czytaj oryginał (ang.) |
| Tiziana Life Sciences advances foralumab towards commercialization with key manufacturing partnership |
Tiziana Life Sciences Ltd (NASDAQ:TLSA) has announced a new agreement with Renaissance Lakewood LLC to advance the development of its lead therapeutic candidate intranasal foralumab. The partnership will focus on optimizing the formulation and scaling up production of the investigational therapy, which is being developed for neurodegenerative and inflammatory diseases. |
proactiveinvestors.com |
2025-02-21 10:52:00 |
Czytaj oryginał (ang.) |
| Tiziana Life Sciences Announces Agreement for Product Development Services with Renaissance Lakewood, LLC |
NEW YORK, Feb. 21, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced a product development services agreement with Renaissance Lakewood LLC (“Renaissance”), a leading Contract Development and Manufacturing Organization (CDMO) focused on nasal drug delivery. This collaboration aims to optimize the current formulation and develop a comprehensive plan for the scale-up of foralumab in a nasal device. Intranasal foralumab is currently under development for treating neurodegenerative and inflammatory diseases or conditions. |
globenewswire.com |
2025-02-21 10:00:00 |
Czytaj oryginał (ang.) |
| Tiziana Life Sciences announces dosing of additional patients in MS Expanded Access Program |
Tiziana Life Sciences Ltd (NASDAQ:TLSA) announced that additional patients with non-active secondary progressive multiple sclerosis (na-SPMS) have been dosed with its investigational therapy intranasal foralumab in its Expanded Access Program. The program now includes 14 patients, with four new patients added to the trial. |
proactiveinvestors.com |
2025-02-18 11:43:42 |
Czytaj oryginał (ang.) |
| Tiziana Life Sciences Announces Dosing of Additional Patients in Multiple Sclerosis Expanded Access Program |
NEW YORK, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced the dosing of an additional four patients in its Intermediate Size Patient Population Expanded Access (ISPPEA) for patients with non-active secondary progressive multiple sclerosis (na-SPMS) who do not qualify for the ongoing Phase 2a study (NCT06292923). |
globenewswire.com |
2025-02-18 10:00:00 |
Czytaj oryginał (ang.) |
| Tiziana Life Sciences says foralumab shows promise in Alzheimer's treatment |
Tiziana Life Sciences Ltd (NASDAQ:TLSA) said its investigational drug, intranasal foralumab, is gaining attention for its potential to address Alzheimer's disease, a condition with limited treatment options. The company's expanded access program for moderate Alzheimer's has allowed the first patient to receive the therapy, offering hope for those battling the disease. |
proactiveinvestors.com |
2025-02-11 14:34:58 |
Czytaj oryginał (ang.) |
| Tiziana Life Sciences Announces TV Interview with First Patient Dosed with Moderate Alzheimer's Disease |
NEW YORK, Feb. 11, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced that its investigational drug, intranasal foralumab, was featured on a prominent News Channel. The segment highlighted the experiences of the first patient dosed in the company's expanded access program for moderate Alzheimer's disease. |
globenewswire.com |
2025-02-11 11:15:00 |
Czytaj oryginał (ang.) |
| Tiziana Life Sciences reports promising preclinical results for nasal anti-CD3 in spinal cord injury |
Tiziana Life Sciences Ltd (NASDAQ:TLSA) has announced positive results from studies of a nasal anti-CD3 monoclonal antibody in traumatic spinal cord injury (SCI). SCI represents a major global health concern with significant effects on mortality and long-term disability, the company said in a statement on Thursday. |
proactiveinvestors.com |
2025-01-23 17:31:31 |
Czytaj oryginał (ang.) |
| Tiziana Life Sciences Announces Positive Results in Treating Spinal Cord Injury With Nasal Anti-CD3 |
NEW YORK, Jan. 23, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced results from studies using a nasal anti-CD3 monoclonal antibody in traumatic spinal cord injury (SCI). |
globenewswire.com |
2025-01-23 17:00:00 |
Czytaj oryginał (ang.) |
| Tiziana Life Sciences not to engage in capital raising activities for the immediate future |
NEW YORK, Jan. 23, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announces its intention not to engage in a capital raising activities for the immediate future. |
globenewswire.com |
2025-01-23 10:54:00 |
Czytaj oryginał (ang.) |
| Tiziana Life Sciences identifies new immune biomarkers in MS patients treated with foralumab |
Tiziana Life Sciences Ltd (NASDAQ:TLSA) has announced the discovery of new immune biomarkers in patients with non-active secondary progressive multiple sclerosis (na-SPMS) treated with its novel therapy nasal foralumab. The company's study detected changes in gene expression starting three months after patients received intranasal foralumab in the ongoing ISPPEA (Expanded Access Program). |
proactiveinvestors.com |
2025-01-22 18:36:13 |
Czytaj oryginał (ang.) |
| Tiziana Life Sciences Announces Discovery of New Immune Biomarkers in Multiple Sclerosis Patients Treated with Nasal Foralumab |
NEW YORK, Jan. 22, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced the discovery of new immune biomarkers in patients with non-active secondary progressive multiple sclerosis (na-SPMS) treated with nasal foralumab. We believe these findings contribute substantially to our understanding of the immune mechanisms underlying the effects of nasal foralumab. |
globenewswire.com |
2025-01-22 18:05:00 |
Czytaj oryginał (ang.) |
| Tiziana Life Sciences' foralumab reduces side effects of discontinuing GLP-1 agonists |
Tiziana Life Sciences Ltd (NASDAQ:TLSA) announced that its intranasal anti-CD3 monoclonal antibody, foralumab, has demonstrated the ability to mitigate the side effects associated with the discontinuation of GLP-1 agonists, medicines used to manage Type 2 diabetes and obesity. GLP-1 agonists, such as semaglutide marketed under brand names like Ozempic and Wegovy, are integral in treating metabolic disorders but often lead to side effects including sarcopenia and bone density loss. |
proactiveinvestors.com |
2025-01-10 12:09:14 |
Czytaj oryginał (ang.) |
| Tiziana Life Sciences welcomes publication of article highlighting foralumab's potential in neurological diseases |
Tiziana Life Sciences Ltd (NASDAQ:TLSA) has announced the publication of a review article in Nature Reviews Neurology that examines the potential of its lead therapeutic candidate intranasal foralumab in treating various neurodegenerative diseases such as Multiple Sclerosis (MS), Alzheimer's disease, ALS, and Parkinson's disease. The article, titled “Immune mechanisms and shared immune targets in neurodegenerative diseases,” emphasizes the immune system's role as a primary driver in diseases like MS or an amplifying factor in conditions such as Alzheimer's, ALS, and Parkinson's. |
proactiveinvestors.com |
2025-01-08 10:45:42 |
Czytaj oryginał (ang.) |
| Tiziana Life Sciences Announces Review Article Published in Nature Highlighting Foralumab's Potential in the Treatment of Neurological Disease |
NEW YORK, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced that a review article titled “Immune mechanisms and shared immune targets in neurodegenerative diseases” was published in Nature Reviews Neurology, highlighting the therapeutic potential of intranasal foralumab in various neurodegenerative diseases including Multiple Sclerosis (MS), Alzheimer's disease, ALS, and Parkinsons disease. |
globenewswire.com |
2025-01-08 09:00:00 |
Czytaj oryginał (ang.) |
| Tiziana Life Sciences doses first Alzheimer's patient with intranasal foralumab |
Tiziana Life Sciences Ltd (NASDAQ:TLSA) announced that it has dosed the first patient with moderate Alzheimer's disease with its lead investigational drug candidate intranasal foralumab. The company said this milestone took place at Brigham and Women's Hospital in Boston as part of a study aimed at addressing neuroinflammation, a key factor in Alzheimer's progression. |
proactiveinvestors.com |
2024-12-17 11:13:23 |
Czytaj oryginał (ang.) |
| Tiziana Life Sciences expands Phase 2 MS trial to additional top US medical institutions |
Tiziana Life Sciences Ltd (NASDAQ:TLSA) announced that it has expanded its Phase 2 clinical trial evaluating intranasal foralumab for non-active secondary progressive multiple sclerosis (SPMS) to additional trial sites across the Northeast of the United States. The trial sites include highly-regarded institutions, including Yale University, Johns Hopkins University, Cornell University, University of Buffalo, University of Massachusetts, and Thomas Jefferson University. |
proactiveinvestors.com |
2024-12-04 10:38:19 |
Czytaj oryginał (ang.) |
| Tiziana Life Sciences secures grant for ALS trial |
Tiziana Life Sciences Ltd (NASDAQ:TLSA) announced that its grant application to the ALS Association has been approved. The company has secured funding under the Hoffman ALS Clinical Trial Awards Program which will be used for a 20-patient study investigating the safety and early efficacy of its investigational drug intranasal foralumab in patients with Amyotrophic Lateral Sclerosis (ALS), a progressive neurodegenerative disease. |
proactiveinvestors.com |
2024-11-19 10:47:55 |
Czytaj oryginał (ang.) |
| Tiziana Life Sciences CEO discusses foralumab potential to enhance Ozempic - ICYMI |
Tiziana Life Sciences Ltd (NASDAQ:TLSA) this week announced positive research findings showing the anti-inflammatory potential of the company's nasal anti-CD3 antibody foralumab when used in combination with semaglutide, a GLP-1 agonist marketed as Ozempic and Wegovy. CEO Ivor Elrifi joined Proactive to discuss the findings. |
proactiveinvestors.com |
2024-11-02 10:18:50 |
Czytaj oryginał (ang.) |
| Tiziana Life Sciences to showcase breakthrough therapies at BIO-Europe 2024 Conference |
Tiziana Life Sciences Ltd (NASDAQ:TLSA) said it will participate in the upcoming BIO-Europe 2024 conference in Stockholm. The event will allow Tiziana to engage with industry leaders, potential collaborators, and investors, emphasizing its recent clinical advancements, particularly data from its combination study involving Ozempic, a GLP-1 agonist. |
proactiveinvestors.com |
2024-11-01 18:31:20 |
Czytaj oryginał (ang.) |
| Tiziana Life Sciences to Participate in BIO-Europe 2024 to Discuss Recent Clinical Advancements, Including Positive GLP-1 Combination Study Data |
NEW YORK, Nov. 01, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced its participation in the BIO-Europe 2024 conference, taking place November 4-6 in Stockholm, Sweden. As part of the conference's partnering meetings, Tiziana will engage with industry leaders, potential collaborators, and investors to discuss recent clinical progress, including data from its combination study involving Ozempic, a GLP-1 agonist. |
globenewswire.com |
2024-11-01 15:00:00 |
Czytaj oryginał (ang.) |
| Tiziana Life Sciences secures funding to advance development of MS and Alzheimer's therapy |
Tiziana Life Sciences Ltd (NASDAQ:TLSA) announced that it has secured up to $10 million in funding through a registered direct offering. The offering includes an initial investment of approximately $5 million raised through the sale of 5,263,158 common shares at $0.95 each, with closing expected around November 1, 2024, The agreement also includes an option allowing the investor to acquire an additional 5,263,158 shares at the same price within 75 days, potentially bringing in another $5 million. |
proactiveinvestors.com |
2024-10-31 10:29:05 |
Czytaj oryginał (ang.) |
| Tiziana Life Sciences Announces Registered Direct Offering of up to approximately $10 Million |
Includes initial funding of approximately $5 million, as well as the option for additional proceeds of approximately $5 million Includes initial funding of approximately $5 million, as well as the option for additional proceeds of approximately $5 million |
globenewswire.com |
2024-10-31 00:29:00 |
Czytaj oryginał (ang.) |
| Tiziana Life Sciences reports promising preclinical results for novel combination therapy targeting obesity |
Tiziana Life Sciences Ltd (NASDAQ:TLSA) has reported positive results from a preclinical study evaluating the combination of its lead development candidate intranasal foralumab and semaglutide, which is marketed by Novo Nordisk (NYSE:NVO) under the brand names Ozempic and Wegovy. The study demonstrated that this combination effectively promotes liver homeostasis and reduces inflammation in preclinical models of diet-induced obesity. |
proactiveinvestors.com |
2024-10-30 12:14:08 |
Czytaj oryginał (ang.) |
| Tiziana Life Sciences awarded $4M to advance Alzheimer's disease research |
Tiziana Life Sciences Ltd (NASDAQ:TLSA) announced that it has secured a $4 million grant from the National Institutes of Health (NIH) to advance research of nasal anti-CD3 as a treatment for Alzheimer's disease. The company has been developing a fully human, anti-CD3 monoclonal antibody called intranasal foramulab, which has demonstrated a favorable safety profile and clinical response in studies to date. |
proactiveinvestors.com |
2024-09-19 13:01:59 |
Czytaj oryginał (ang.) |
| Tiziana Life Sciences names new chief executive |
Tiziana Life Sciences Ltd (NASDAQ:TLSA) has announced the appointment of Ivor Elrifi as its CEO, replacing acting CEO Gabriele Cerrone who will remain in his role as executive chairman of the board. The company highlighted that Elfiri previously served as the global head of the Patent Group at Cooley since 2014, and before that, he led the Patents division at Mintz Levin from 1999 to 2014. |
proactiveinvestors.com |
2024-08-19 12:53:45 |
Czytaj oryginał (ang.) |
| Tiziana Life Sciences Appoints New Chief Executive Officer |
NEW YORK, Aug. 19, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced the appointment of Ivor Elrifi as its Chief Executive Officer (CEO), effective immediately. |
globenewswire.com |
2024-08-19 11:00:00 |
Czytaj oryginał (ang.) |
| Tiziana Life Sciences secures FDA Fast Track status for MS therapy intranasal foralumab |
Tiziana Life Sciences Ltd (NASDAQ:TLSA) shares moved higher after the biotechnology firm revealed the US Food and Drug Administration (FDA) has granted Fast Track designation to its intranasal formulation of foralumab for the treatment of non-active Secondary Progressive Multiple Sclerosis. The FDA's Fast Track designation is intended to support the development of and review of drugs that address an unmet medical need. |
proactiveinvestors.com |
2024-07-24 13:40:00 |
Czytaj oryginał (ang.) |
| Tiziana Life Sciences Granted FDA Fast Track Designation |
NEW YORK, July 24, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for its intranasal formulation of foralumab, a fully human anti-CD3 monoclonal antibody, for the treatment of non-active Secondary Progressive Multiple Sclerosis (na-SPMS). |
globenewswire.com |
2024-07-24 11:00:00 |
Czytaj oryginał (ang.) |
| Tiziana Life Sciences secures $3.4M in non-dilutive funding |
Tiziana Life Sciences Ltd (NASDAQ:TLSA) announced it has received non-dilutive funding of $3.4 million which will be used to advance its investigation therapy foralumab. The company highlighted that foralumab is the only fully human anti-CD3 monoclonal antibody (mAb), which binds to the T cell receptor and dampens inflammation by modulating T cell function, therefore suppressing effector features in multiple immune cell subsets. |
proactiveinvestors.com |
2024-06-28 15:34:42 |
Czytaj oryginał (ang.) |
| Tiziana Receives $3.4 Million in Non-Dilutive Funding |
NEW YORK, June 28, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough therapies in neurodegenerative disease secondary to active neuroinflammatory processes today announced that it had received non-dilutive funding of $3.4 million and issued a corporate update video available here. |
globenewswire.com |
2024-06-28 15:01:00 |
Czytaj oryginał (ang.) |
| Tiziana Life Sciences secures FDA approval to dose first patient with moderate Alzheimer's with investigational therapy |
Tiziana Life Sciences Ltd (NASDAQ:TLSA) announced that it has won approval from the US Food and Drug Administration under an Expanded Access IND to dose its first patient with moderate Alzheimer's disease with its investigational therapeutic intranasal foralumab. Expanded access INDs allow patients to gain access to investigational drugs, biologics and medical devices to treat serious diseases and conditions for which there are no comparable or satisfactory therapy options outside of clinical trials, the biopharmaceutical company said. |
proactiveinvestors.com |
2024-06-26 12:36:07 |
Czytaj oryginał (ang.) |
| Tiziana Life Sciences to Dose First Patient with Moderate Alzheimer's Disease with Foralumab |
NEW YORK, June 26, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced that the U.S. Food and Drug Administration (FDA) has allowed intranasal foralumab to be used under an Expanded Access (EA) IND in its first patient with moderate Alzheimer's disease. |
globenewswire.com |
2024-06-26 11:00:00 |
Czytaj oryginał (ang.) |
| Tiziana Life Sciences seeks FDA Fast Track Designation for foralumab in MS treatment |
Tiziana Life Sciences Ltd (NASDAQ:TLSA), said it is seeking Fast Track Designation approval from the US Food and Drug Administration (FDA) for its intranasal foralumab therapy to treat non-active, secondary-progressive multiple sclerosis (na-SPMS). Foralumab, a fully human anti-CD3 monoclonal antibody, has demonstrated the ability to induce T regulatory cell production when administered intranasally. |
proactiveinvestors.com |
2024-06-11 14:05:47 |
Czytaj oryginał (ang.) |
| Tiziana Life Sciences reports qualitative improvement in MS patients treated with lead asset |
Tiziana Life Sciences Ltd (NASDAQ:TLSA) has unveiled encouraing results from patients with non-active Secondary Progressive Multiple Sclerosis (na-SPMS) enrolled in its Expanded Access Program who have been receiving its drug asset foralumab for at least six months. The company is developing foralumab, the only fully human anti-CD3 mAb, which has demonstrated a favorable safety profile and clinical response in patients in studies to date. |
proactiveinvestors.com |
2024-06-06 14:13:05 |
Czytaj oryginał (ang.) |